C1 Inhibitor Treatment Registry to Assess the Safety and Immunological Profile of Ruconest in the Treatment of HAE Attacks
Status: Completed
Location: See all (15) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
This is a non-interventional treatment Registry of Hereditary Angioedema (HAE) patients treated with C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (rhC1INH / Ruconest), to observe adverse events and insufficient efficacy, and to assess the immunological profile following single and repeated treatment with Ruconest.
Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:
• Decision to treat the HAE patient with C1 inhibitor (either Ruconest or pdC1INH)
• Patients must give written informed consent
Locations
Other Locations
Bulgaria
UMHAT Alexandrovska EAD
Sofia
Croatia
General Hospital Sibenik
Šibenik
KBC Split
Split
CHC Sestre milosrdnice
Zagreb
France
Hospital A Michallon, CHU Grenoble
La Tronche
Germany
Charite Universitatsmedizin Berlin
Berlin
Hungary
Semmelweis University, 3rd Department of Internal Medicine
Budapest
Italy
Ospedale Luigi Sacco
Milan
Norway
Alesund Hospital
Ålesund
Stavanger University Hospital
Stavanger
Poland
University Hospital Krakow
Krakow
Slovakia
Bratislava University Hospital
Bratislava
University Hospital Martin
Martin
Slovenia
University Clinic Golnik
Golnik
Sweden
Ryhof County Hospital
Jönköping
Time Frame
Start Date: 2011-07
Completion Date: 2024-12-10
Participants
Target number of participants: 181
Treatments
Hereditary Angioedema
Related Therapeutic Areas
Sponsors
Leads: Pharming Technologies B.V.